BRAND NAME:

Tuglif-M

GENERIC NAME:

Ertugliflozin + Metformin HCl

THERAPEUTIC SEGMENT:

Antidiabetic

INDICATIONS:

Tuglif-M is a combination of ertugliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

BRIEF DESCRIPTION:

Ertugliflozin + Metformin is an orally bioavailable, fixed-dose combination therapy for the management of type 2 diabetes mellitus (T2DM). Ertugliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, lowers blood glucose levels by reducing renal glucose reabsorption, promoting glycosuria, and contributing to weight loss and blood pressure reduction. Metformin, a biguanide, decreases hepatic glucose production, enhances insulin sensitivity, and improves peripheral glucose uptake. Together, these agents provide a complementary mechanism of action to achieve better glycemic control while also offering potential cardiovascular and renal benefits.

DOSAGE FORM:

Tablets

2.5mg+1000mg

7.5mg+1000mg